文献速递消化系统肿瘤

吉西他滨联合白蛋白紫杉醇序贯或交替FOLFIRI.3一线治疗转移性胰腺癌的随机II期研究(FIRGEMAX)

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
PubMed 文献 · Eur J Cancer · 2020-07-02

FIRGEMAX是一项随机II期研究,纳入127例初治转移性胰腺腺癌患者,比较吉西他滨联合白蛋白紫杉醇每2个月与FOLFIRI.3交替(A组)和单用吉西他滨联合白蛋白紫杉醇至进展(B组)。主要终点6个月无进展生存率在mITT人群中A组为45.2%、B组为23.3%,未达到预设的60%目标;交替策略可行性好、毒性可管理。

要点

  • 交替组6个月PFS率45.2%,单药组23.3%,未达预设60%目标
  • 交替组腹泻和中性粒细胞减少发生率更高,但无毒性死亡
  • 交替策略在能完成>2个月治疗的患者中可行且毒性可管理

核心结论

  • 吉西他滨联合白蛋白紫杉醇与FOLFIRI.3每2个月交替的策略在能完成>2个月治疗的患者中可行且有效,毒性可管理。
  • 主要终点6个月PFS率未达到预设的60%目标。

研究设计与样本

  • 随机II期研究,纳入化疗初治、胆红素≤1.5倍正常上限、体能状态0-2的转移性胰腺腺癌患者。
  • 主要目标是将6个月PFS率从40%(H0)提高至60%(H1),采用二项精确法估算需124例;分析在预设的mITT和PP人群中进行。

主要发现

  • III-IV级毒性(A/B组%):腹泻12.5/1.7,中性粒细胞减少46.9/31(含发热性中性粒细胞减少1.6/0),皮肤毒性6.3/13.8,周围神经病变6.3/8.6;无毒性死亡。
  • 客观缓解率A组40.3%(95%CI:28.1-53.6),B组26.7%(95%CI:16.1-39.7)。
  • mITT人群6个月PFS率A组45.2%(单侧95%CI:34.3-56.4),B组23.3%(单侧95%CI:14.3-32.3)。
  • PP人群中A组与B组中位PFS分别为7.6个月和6个月,中位OS分别为14.5个月和12.2个月。

关键数值与推荐

  • 主要终点6个月PFS率预设H0为40%、H1为60%,需124例患者。
  • mITT人群6个月PFS率A组45.2%(单侧95%CI:34.3-56.4),B组23.3%(单侧95%CI:14.3-32.3)。
  • 客观缓解率A组40.3%(95%CI:28.1-53.6),B组26.7%(95%CI:16.1-39.7)。

临床怎么用

  • 对能耐受并完成>2个月治疗的转移性胰腺腺癌患者,可考虑吉西他滨联合白蛋白紫杉醇与FOLFIRI.3每2个月交替的一线策略。
  • 交替方案需关注腹泻和中性粒细胞减少等毒性并做好监测管理。

局限性

  • 为随机II期研究,主要终点未达到预设的60%目标。
  • 结论限定于能完成>2个月治疗的患者,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemotherapy is effective in metastatic pancreatic adenocarcinoma (mPA), but new approaches are still needed to improve patients' survival and quality of life. We have previously published good efficacy and tolerability results on a sequential treatment strategy of gemcitabine followed by an intensified FOLFIRI (5FU+irinotecan) regimen. In the present study, we evaluated the same sequence but replaced gemcitabine by the new gemcitabine + nab-paclitaxel standard first-line combination. PATIENTS AND METHODS: We randomised chemotherapy-naive patients with proven mPA, bilirubin levels ≤1.5 upper limit of normal values and performance status 0-2 to alternately receive gemcitabine + nab-paclitaxel for 2 months then FOLFIRI.3 for 2 months in arm A, or gemcitabine + nab-paclitaxel alone until progression in arm B. The primary objective was to increase the 6-month progression-free survival (PFS) rate from 40% (H0) to 60% (H1); using the binomial exact method, 124 patients were required. Analyses were carried out in preplanned modified intention-to-treat (mITT) and per-protocol (PP) populations. RESULTS: Between November 2015 and November 2016, 127 patients were enrolled. Main grade III-IV toxicities (% in arm A/B) were: diarrhoea (12.5/1.7), neutropenia (46.9/31, including febrile neutropenia: 1.6/0), skin toxicity (6.3/13.8), and peripheral neuropathy (6.3/8.6). No toxic deaths occurred. The objective response rate was 40.3% (95% confidence interval [CI]: 28.1-53.6) in arm A and 26.7% (95% CI: 16.1-39.7) in arm B. The primary end-point (6-month PFS rate) was 45.2% [one-sided 95% CI: 34.3-56.4] in arm A and 23.3% in arm B [one-sided 95% CI: 14.3-32.3] in the mITT population. In the PP population, median PFS and OS were 7.6 months and 6 months and 14.5 months and 12.2 months in arm A and B, respectively. CONCLUSIONS: The FIRGEMAX strategy with gemcitabine + nab-paclitaxel alternating with FOLFIRI.3 every 2 months, appears feasible and effective, with manageable toxicities, in patients able to reach >2mo of treatment. TRIAL REGISTRATION INFORMATION: EudraCT: 2014-004449-28: NCT: 0282701.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Rinaldi Y, Pointet AL, Khemissa Akouz F, et al. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX). Eur J Cancer. 2020. PMID: 32623182. doi:10.1016/j.ejca.2020.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。